Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Asian Penny Stocks Spotlight: Viva Biotech Holdings And Two More To Consider

In This Article:

Amidst global economic uncertainties, Asian markets have shown resilience, with a focus on growth strategies to navigate challenges such as trade tensions and inflationary pressures. In this context, penny stocks—often representing smaller or newer companies—continue to capture investor interest due to their potential for significant returns. While the term may seem outdated, these stocks can offer a blend of affordability and growth potential when backed by strong financials.

Top 10 Penny Stocks In Asia

Name

Share Price

Market Cap

Financial Health Rating

Yangzijiang Shipbuilding (Holdings) (SGX:BS6)

SGD2.35

SGD9.28B

★★★★★☆

Lever Style (SEHK:1346)

HK$1.28

HK$812.53M

★★★★★★

Bosideng International Holdings (SEHK:3998)

HK$4.23

HK$48.48B

★★★★★★

Activation Group Holdings (SEHK:9919)

HK$0.89

HK$662.82M

★★★★★★

Xiamen Hexing Packaging Printing (SZSE:002228)

CN¥3.05

CN¥3.53B

★★★★★★

Beng Kuang Marine (SGX:BEZ)

SGD0.21

SGD41.83M

★★★★★★

Interlink Telecom (SET:ITEL)

THB1.53

THB2.13B

★★★★☆☆

China Zheshang Bank (SEHK:2016)

HK$2.36

HK$79.91B

★★★★★★

Playmates Toys (SEHK:869)

HK$0.60

HK$708M

★★★★★★

Jiumaojiu International Holdings (SEHK:9922)

HK$3.30

HK$4.61B

★★★★★★

Click here to see the full list of 1,162 stocks from our Asian Penny Stocks screener.

Let's uncover some gems from our specialized screener.

Viva Biotech Holdings

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Viva Biotech Holdings is an investment holding company that provides structure-based drug discovery services to biotech and pharmaceutical clients globally, with a market cap of HK$3.17 billion.

Operations: The company's revenue is primarily generated from its Drug Discovery Services, which account for CN¥780.09 million, and its Contract Development Manufacture Organisation (CDMO) and Commercialisation Services, contributing CN¥1.21 billion.

Market Cap: HK$3.17B

Viva Biotech Holdings, with a market cap of HK$3.17 billion, focuses on drug discovery and manufacturing services. The company generates significant revenue from its Drug Discovery Services (CN¥780.09 million) and CDMO/Commercialisation Services (CN¥1.21 billion). Despite being unprofitable, it maintains a positive cash flow with a sufficient runway for over three years. Its short-term assets exceed liabilities but fall short for long-term obligations. Recent expansions include a new branch in Boston, enhancing its global presence and collaboration opportunities within the biopharma sector, potentially strengthening its service capabilities across North America and beyond amidst high share price volatility.